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OBJECTIVE: The early identiﬁcation of coronary artery disease
CAD is important in preventing subsequent premature mortal-
ity and disability, and potentially reducing the health care burden
associated with advanced disease. The objective of this study was
to evaluate the cost-effectiveness of myocardial perfusion scintig-
raphy (MPS) for patients with suspected chronic CAD in the UK.
METHOD: A decision-analytic model was developed to repre-
sent the diagnosis and management of patients with suspected
XCAD. A “diagnostic” module represented alternative diagnos-
tic strategies based on combinations of exercise ECG (ExECG),
MPS and coronary angiography (CA). A ‘treatment’ module rep-
resented initial patient management, based on diagnostic results.
Finally, subsequent patient experience (mortality, future MIs and
revascularisation procedures) according to severity of disease
and therapy at outset was represented as a Markov process.
Event risks, therapy effectiveness (risk reductions), diagnostic
accuracy and risks were obtained from published studies. Test
and intervention costs were based on NHS reference values.
Long-term costs of patient management for patients with CAD
in the UK, and health state utilities were based on published
values. The model was used to test parameter assumptions,
including duration of therapy effectiveness (base case: 5–10
years) and delay to diagnosis of false negatives (those missed in
initial work-up: base case 1 year). RESULTS: Compared with
ExECG, MPS was cost-effective when the underlying risk of
CAD was <50% (cost saving at <30%). Compared with a strat-
egy of no testing MPS was cost-effective at an underlying risk of
>20%. At ≥80% risk direct CA was cost saving and more effec-
tive than alternative diagnostic strategies. Adding MPS as a
second-line test for patients positive or indeterminate on ExECG
was cost-effective for intermediate risk patients. CONCLU-
SION: MPS is likely to be an economically attractive ﬁrst-line or
second-line test in the diagnostic work-up of symptomatic
patients with intermediate risk of chronic CAD.
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OBJECTIVE: The Losartan Intervention For Endpoint Reduc-
tion in Hypertension study (LIFE) was a double-masked, ran-
domized trial of losartan versus atenolol in 9193 patients with
essential hypertension and left ventricular hypertrophy ascer-
tained by electrocardiography. Losartan reduced the primary
composite end point of cardiovascular death, myocardial infarc-
tion, or stroke by 13% (p = 0.021) and reduced the risk of stroke
by 25% (p = 0.001), despite a comparable degree of blood pres-
sure control. We aimed to evaluate the cost-effectiveness of losar-
tan compared with atenolol in LIFE from a German health care
system’s perspective. METHODS: Discounted life expectancy
with stroke, study medication use and quality of life by stroke
status were estimated directly from the LIFE trial. The trial data
were supplemented with data from Germany on discounted
direct lifetime costs of stroke (€43,129) and discounted life
expectancy in individuals without stroke. Quality-adjusted life
years were estimated by weighting life years by health-related
quality of life as measured by visual analogue scale data collected
in the LIFE trial. RESULTS: The lower cumulative incidence 
of stroke for losartan at 5.5 years (4.9%) as compared with
atenolol (6.5%) (p = 0.003) was estimated to reduce stroke-
related direct costs by €691 per patient and thus to offset 52%
of the incremental medication cost in patients receiving losartan.
The cost per quality-adjusted life year gained was €23,630 (95%
CI: −1276 to 95,115) for losartan-based versus atenolol-based
treatment. CONCLUSION: The clinical beneﬁt of losartan in
Germany is achieved at a cost well within accepted thresholds
for cost-effectiveness. A substantial proportion of the incremen-
tal cost for losartan is offset due to strokes prevented.
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OBJECTIVES: To assess the cost-utility of Eprosartan (Teveten)
compared to the two most commonly used ACE-inhibitors in
Sweden. METHODS: Cost-effectiveness from the societal and
health-care payer perspective was evaluated using Monte Carlo-
simulation within a Markov framework. The risk of cardiovas-
cular and cerebrovascular events was based on the Framingham
study. Costs (2005 Swedish Kronor, SEK, 1€ = 9,22 SEK) and
utilities were based on published sources. The treatments effect
on systolic blood pressure (SBP) was taken from randomized
clinical trials and the risk reduction due to lower SBP was based
on metaanalysis. Treatment lasted for 5 years and patients were
followed for the remainder of their life. 3% discounting of costs
and effects was applied. RESULTS: From the health-care payer
perspective, the cost-effectiveness compared to Enalapril ranged
from 226,098 SEK/QALY for a 40 year-old non-diabetic cohort
with 50% males (corresponding to a 5-year risk of 4.4%) to
35,253 SEK/QALY for 80-year olds with diabetes (correspond-
ing to a 5-year risk of 41.7%). The corresponding ﬁgures com-
pared to Ramipril was 143,857 SEK/QALY—10,263 SEK/
QALY. From a societal perspective (including cost in added years
of life) the ﬁgures were 176,237 SEK/QALY—283,882 SEK/
QALY and 93,996 SEK/QALY—258,891 SEK/QALY. CON-
CLUSIONS: The incremental cost-effectiveness ratios all fall
below the commonly used threshold value of 500,000 SEK per
QALY, even if costs in added years of life are included which
gives higher ratios for treatments that extend life in older age
groups. Eprosartan thus appears to be a cost-effective strategy
compared to Enalapril or Ramipril.
PCV54
COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTIC METHODS
IN THE MANAGEMENT OF PATIENTS WITH SYMPTOMATIC,
LOWER LIMB PERIPHERAL ARTERIAL DISEASE
Aguiar-Ibáñez R1, Craig D1, Collins R1, Cranny G1, Burch J1,
Wright K1, Berry E2, Gough M3, Kleijnen J4,Westwood M1
1Centre for Reviews and Dissemination,York, UK, 2EB Imagistics Ltd,
Leeds, UK, 3Leeds General Inﬁrmary, Leeds, UK, 4Kleijnen Systematic
Reviews Ltd,York, UK
